# US 2024/0368212 A1 · Selective isonitrile inhibitors of cytochrome p450 subtypes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0368212 A1
- Document ID: US20240368212A1
- Status: Published application
- Kind: A1
- Application number: 18/686,734
- Filed: 2022-08-25
- Published: 2024-11-07
- Earliest claimed: 2021-08-26
- Assignees: Brandeis University
- Applicants: Brandeis University
- Inventors: Thomas Charles Pochapsky; Nathan Ross Wong; Reethy Sundar
- Web page: https://patentgrep.com/patent/US20240368212A1

## CPC

- A61P 31/06: for tuberculosis
- C07J 41/0094: {containing nitrile radicals, including thiocyanide radicals}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 35/00: Antineoplastic agents
- C07J 41/0022: {Isocyanates; Isothiocyanates}
- C07J 41/005: {the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives}
- C07J 41/0055: {the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are steroid or steroid-like compounds including at least one isonitrile group and which inhibit the activity of a cytochrome P450 enzyme, as well as compositions including the compounds. Also included are methods of inhibiting activity of a cytochrome P450 in a subject having a steroid-responsive cancer, a Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound including at least one isonitrile group or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.

## Claims

### Claim 1

A compound represented by Formula 1 and comprising at least one isonitrile (—NC), or a pharmaceutically acceptable salt thereof
wherein
X1 is N, N(R11), C(R11), O, S, S(═O), C(═Y), C(═N—OR11), C(R11)(R12), or L(N≡C);
X2 is N, N(R21), C(R21), O, S, S(═O), C(═Y), C(═N—OR21), C(R21)(R22), or L(N≡C);
X3 is N, N(R31), C(R31), O, S, S(═O), C(═Y), C(═N—OR31), C(R31)(R32), or L(N≡C);
X4 is N, N(R41), C(R41), O, S, S(═O), C(═Y), C(═N—OR41), C(R41)(R42), or L(N≡C);
X5 is C, N, S, C(R51), or L(N≡C);
X6 is N, N(R61), C(R61), O, S, S(═O), C(═Y), C(═N—OR61), C(R61)(R62), or L(N≡C);
X7 is N, N(R71), C(R71), O, S, S(═O), C(═Y), C(═N—OR71), C(R71)(R72), or L(N≡C);
X8 is C, N, S, C(R81), or L(N≡C);
X9 is C, N, S, C(R91), or L(N≡C);
X10 is C, N, S, C(R101), or L(N≡C);
X11 is N, N(R111), C(R111), O, S, S(═O), C(═Y), C(═N—OR111), C(R111)(R112), or L(N≡C);
X12 is N, N(R121), C(R121), O, S, S(═O), C(═Y), C(═N—OR121), C(R121)(R122), or L(N≡C);
X13 is C, N, S, C(R131), or L(N≡C);
X14 is C, N, S, C(R141), or L(N≡C);
X15 is N, N(R151), C(R151), O, S, S(═O), C(═Y), C(═N—OR151), C(R151)(R152) or L(N≡C);
X16 is N, N(R161), C(R161), O, S, S(═O), C(═Y), C(═N—OR161), C(R161)(R162) or L(N≡C);
X17 is N, N(R171), C(R171), O, S, S(═O), C(═Y), C(═N—OR171), C(R171)(R172) or L(N≡C);
Y is N, O, S, or C1-C12 alkyl in which any carbon-carbon single bond is optionally replaced by a carbon-carbon double or triple bond, any methylene is optionally replaced by O, S, or NR10, and optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, cyano, amino, and oxo;
R10, R11, R12, R21, R22, R31, R32, R41, R42, R51, R61, R62, R71, R81, R91, R101, R111, R112, R121, R122, R131, R141, R151, R152, R161, R162, R171, and R172 are each independently hydrogen, deuterium, hydroxyl, halogen, C1-C12 alkyl in which any carbon-carbon single bond is optionally replaced by a carbon-carbon double or triple bond, any methylene is optionally replaced by O, S, Si, Ge, P, or NR10, and optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, cyano, amino, and oxo;
L is a single bond or a C1-C12 alkyl in which any carbon-carbon single bond is optionally replaced by a carbon-carbon double or triple bond, any methylene is optionally replaced by O, S, Si, Ge, P, or NR10, and optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, cyano, amino, and oxo;
optionally, any two adjacent substituents may form a C5-C7 carbocyclic ring or a C2-C7 heterocyclic ring;
optionally, any two substituents on the same carbon may form a carbocyclic or heterocyclic spiro ring system with any of rings A-D; and
represents a single or a double bond provided that rings A, B, C, and D are not simultaneously aromatic.

### Claim 2 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the compound of Formula 1 is represented by one of Formulae 1-A to Formulae 1-E:

### Claim 3 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein R10, R11, R12, R21, R22, R31, R32, R41, R42, R51, R61, R62, R71, R81, R91, R101, R111, R112, R121, R122, R131, R141, R151, R152, R151, R162, R171, and R172 are each independently:
hydrogen, deuterium, halogen, aldehyde, alkylene aldehyde, ketone, alkylene ketone, ester, alkylene ester, amide, alkylene amide, sulfonamide, alkylene sulfonamide, carbamate, alkylene carbamate, urea, alkylene urea, sulfonyl urea, alkylene sulfonyl urea, carboxylic acid, alkylene carboxylic acid, cyano, hydroxyl, thiol, nitro, acyl hydrazide, sulfonyl hydrazide, phosphoryl hydrazide, acyl hydrazone, sulfonic acid, alkylene sulfonic acid, sulfonate, alkylene sulfonate, amine, alkylene amine, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C1-C12 alkoxy, C1-C12 alkylthio, C3-C7 cycloalkyl, C1-C6 alkyl(C3-C7 cycloalkyl), C1-C6 alkyl(C3-C7 cycloalkenyl), C3-C7 cycloalkenyl, C2-C7 heterocycloalkyl, C2-C7 heterocycloalkenyl, C1-C6 alkyl(C2-C7 heterocycloalkyl), C1-C6 alkyl(C2-C7 heterocycloalkenyl), C6-C12 aryl, C2-C12 heteroaryl, C1-C6 alkyl (C2-C12 heteroaryl), optionally substituted with hydroxyl, halogen, deuterium, Si(Q3)(Q4)(Q5), —Ge(Q3)(Q4)(Q5), —B(Q6)(Q7), —P(═O)(Q8)(Q9), —P(Q8)(Q9), wherein Q1 to Q9 are each independently: hydrogen; deuterium; halogen, hydroxyl; cyano; C1-C6 alkyl; C2-C6 alkenyl; C2-C6 alkynyl; C1-C6 alkoxy; C3-C6 carbocyclic; or C2-C6 heterocyclic.

### Claim 4 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the compound is one of the following compounds:

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and optionally comprising an additional active agent.

### Claim 7

(canceled)

### Claim 7 (depends on 1)

A composition comprising:
a plurality of encapsulated nanoparticles, wherein each of the nanoparticles independently comprises
a core comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and
an outer shell at least partially encapsulating the core.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the additional active agent comprises a steroid, an antibacterial agent, an anti-cancer agent, an anti-parasitic agent, an anti-fungal agent, or a combination thereof.

### Claim at position 10

8-11. (canceled)

### Claim 12 (depends on 7)

The composition of claim 7, further comprising a targeting moiety linked to the outer shell, wherein the targeting moiety comprises a protein, a nucleic acid, a nucleic acid analog, a carbohydrate, an antibody, a small molecule, or a combination thereof.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

A method for targeted delivery of a cytochrome P450 (CYP) inhibitor to a target region in a subject in need thereof, wherein the target region is a cell, tissue, organ, or organ system to which the targeting moiety binds, and the method comprises administering the composition of claim 12 to the subject.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject has a steroid-resistant cancer and the target region is a tumor.

### Claim 17 (depends on 1)

A method of inhibiting activity of a cytochrome P450 (CYP) in a subject having a steroid-responsive cancer, an antibiotic-resistant Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject has a steroid-responsive cancer and the CYP comprises CYP17A1.

### Claim 19 (depends on 17)

The method of claim 17, wherein the subject has an antibiotic-resistant Mycobacterium tuberculosis infection and the CYP comprises CYP124A1, CYP125A1, CYP142A1, or a combination thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein the subject has a fungal infection or a trypanosome infection and the CYP comprises CYP51.

### Claim 21 (depends on 1)

A method of treating a steroid-responsive cancer in a subject comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt thereof, in an amount effective to treat the steroid-responsive cancer in the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the steroid-responsive cancer is prostate cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, or a combination thereof.

### Claim at position 22

23-36. (canceled)

### Claim 37

A method providing a chemical structure of an isonitrile inhibitor of a cytochrome P450 comprising (a) oxidizing a parent compound with a cytochrome P450 to provide an oxidation product comprising an oxidized functional group; (b) determining a chemical structure of the oxidation product; and (c) replacing the oxidized functional group with a carbon-isonitrile functional group to provide a structure of an isonitrile inhibitor of the cytochrome P450.

### Claim 38 (depends on 37)

The method of claim 37, wherein the parent compound comprises a steroid or a steroid derivative.

### Claim 39 (depends on 37)

The method of claim 37, wherein the oxidized functional group is an alcohol, an aldehyde, a ketone, or a carboxylic acid.

### Claim 40 (depends on 37)

The method of claim 37, wherein the parent compound is androsterone and the cytochrome P450 is CYP106A2.
